Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

452.6

$million

Invested

97

innovative

Projects

12

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2021-2022

Annual Report

Working Together to Address the Global Threat of Antimicrobial Resistance

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
Wellcome
UK Government
BARDA
NIAID
Novo Nordisk Foundation
The Public Health Agency of Canada

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

03.06.24

 

8th AMR Conference

03.15.24

 

COMBINE Webinar | Development of Target Product Profiles for Antibiotics

06.03.24

 

Boston Bacterial Meeting 2024

CARB-X News

  • 02.13.2024  |  CARB-X funds the Myers Research Group to develop enhanced oral antibiotics to treat a range of serious drug-resistant bacterial infections full release

  • 02.08.2024  |  CARB-X funds Visby Medical to develop a portable rapid diagnostic for gonorrhea including antibiotic susceptibility full release

  • 01.18.2024  |  CARB-X is funding Syntiron to develop a maternal vaccine to prevent neonatal sepsis full release

See All News

In The News

  • 10.29.2023  |  What’s the Superbug Worst Case Scenario? We Ask a Scientist About Antibiotic Resistance full story

  • 09.26.2023  |  The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably. full story

  • 08.27.2023  |  Superbugs: why it’s so hard to stop the ‘silent pandemic’ full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.